Vitrafy Life Sciences (VFY) Q3 2025 TU earnings summary

Operational and Commercial Highlights

• Completed Phase 1 blood platelet study with the US Army Institute of Surgical Research, achieving over 88% post-thaw recovery and exceeding regulatory standards for human health applications.

• Awarded AUD 4.8 million Industry Growth Program grant from the Australian government to accelerate VCU2 development and commercialisation.

• Expanded US operations with the appointment of a VP of Business Development and ongoing pipeline development in blood products, cell/gene therapy, and animal health.

• Continued strong progress in aquaculture and bovine semen cryopreservation, with a 55.3% CAGR in salmon milt packs since 2022 and paid pilot discussions with domestic providers.

• Ongoing development of VCU2 and LifeChain software, with launches targeted for H2 CY2025 and H1 FY2026, respectively.

Financial Performance and Position

• Maintained robust liquidity with approximately AUD 34 million in cash and term deposits at quarter-end.

• Average monthly cash outflow was about AUD 1.1 million, with a net cash movement of AUD (0.5) million for the quarter.

• Expenditure for the quarter totaled AUD 3.05 million, including AUD 341,000 paid to directors and related parties.

• Banked the first half of the government grant in March, with revenue recognized as project costs are incurred.

• Estimated quarters of funding available is 39.4 based on cash and cash equivalents, or 95.8 including term deposits.

Strategic and Market Developments

• Joint marketing and education initiatives planned with the US Army Institute of Surgical Research to promote cryopreservation technology.

• Actively engaging with US blood banks and biobanks, including the Blood Centers of America, for potential partnerships.

• No-cryoprotectant technology eliminates toxic washout steps and simplifies processes, serving as a key differentiator.

• Ongoing optimization and validation of no-cryoprotectant protocols as part of Phase II with the US military.

• Focus remains on commercialisation, scaling US operations, and building the business development pipeline ahead of next-generation device launches.